---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-287903"
form_type: "8-K"
ticker: null
cik: "0001445499"
company_name: "IMPEL PHARMACEUTICALS INC"
filed_at: "2023-12-04T23:59:59+00:00"
generated_at: "2026-06-07T18:40:49.772849+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Impel Pharmaceuticals CFO Michael Kalb resigns effective Dec 31, 2023

## Summary
- CFO Michael Kalb gave notice on Dec 1, 2023; last day is Dec 31, 2023.
- Resignation not due to any disagreement with company's operations, policies, or practices.
- No successor or interim CFO named; Leonard Paolillo remains Interim President & CEO.

## SEC filing metadata
- accession: 0001193125-23-287903
- form_type: 8-K
- cik: 0001445499
- company_name: IMPEL PHARMACEUTICALS INC
- filed_at: 2023-12-04T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1445499/000119312523287903/0001193125-23-287903-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1445499/000119312523287903/d596112d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-287903
- JSON: https://secwatch.observer/filing/0001193125-23-287903.json
- Plain text: https://secwatch.observer/filing/0001193125-23-287903.txt

## Key facts
- Executive change
  Michael Kalb resigned as Chief Financial Officer at IMPEL PHARMACEUTICALS INC.
  - Action: resigned
  - Role: Chief Financial Officer
  source text: On December 1, 2023, Michael Kalb gave notice of his resignation from his position as Chief Financial Officer of Impel Pharmaceuticals Inc. (the “ Company ”) with his last day to be December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1445499/000119312523287903/0001193125-23-287903-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.